Considering the biological contributions of the 12-LOX enzymes (mouse 12/15-LOX and human 12-LOX) to T1D and other inflammatory disorders, the development of enzyme inhibitors offers an attractive approach to disease modification. This evidence concerns the gene ALOX12 and type 1 diabetes mellitus.